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in clinical decision making. We would expect poor performance if
NT-proBNP were to be used for rule-out decisions in patients
with reduced GFR.
It is unfortunate that the investigators (1) did not undertake
BNP testing in their entire cohort so that true comparative
diagnostic performance could be evaluated. On the basis of their
data, we would disagree with their conclusion that NT-proBNP is
useful for diagnosing CHF across a wide range of renal functions.
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REPLY
Lamb and colleagues attempt to compare the results of our study
to their previously published (1) data, derived from a small cohort
of nondyspneic subjects (the vast majority of whom did not have
heart failure [HF]). These comparisons are uninformative, and the
more appropriate approach would be to examine our data in the
context of the currently available data examining the utility of
B-type natriuretic peptide (BNP) in the breathless patient (with
and without HF) (2).
In our study, the area under the receiver operating characteristic
curve (AUC) for amino-terminal pro-B-type natriuretic peptide
(NT-proBNP) for diagnosis of acute HF in those with moderate
or worse chronic kidney disease (CKD) was 0.88, comparable to
the data from such patients in the Breathing Not Properly
Multinational Study renal analysis (AUC between 0.81 and 0.86)
(2). It is of great interest to us that specificity for BNP in those
with CKD was not reported (2); however, with such similar AUC,
there is little chance that the specificity of BNP in those with CKD
is any different than demonstrated for NT-proBNP in our study.
We point out that the specificity of NT-proBNP1200 pg/ml for
acute HF in patients with CKD was 72%, comparing favorably to
the overall specificity of 76% reported among all subjects in the
Breathing Not Properly Multinational Study of BNP (3). As well,
NT-proBNP 300 pg/ml had 100% negative predictive value in
patients with CKD in our study, and concentrations of NT-
proBNP were also strongly prognostic in those with CKD.
Thus, although correlations between renal function and BNP or
NT-proBNP may differ, at optimal cut-points it would be rather
hard to argue that a clinically meaningful difference between BNP
and NT-proBNP exists in those with CKD, and the assertion by
Lamb and colleagues that NT-proBNP has “unacceptable perfor-
mance” in the patient with CKD is not accurate.
Lamb and colleagues quite incorrectly suggest that we asserted
NT-proBNP testing to be “unaffected” by renal function. We
emphasized the effects of renal function on NT-proBNP, but
concluded “even in the presence of impaired renal function,
NT-proBNP measurement is a valuable tool for the diagnostic and
prognostic evaluation of dyspneic patients,” a conclusion supported
by our data.
Whereas observational studies demonstrate that CKD leads to
elevations in both BNP and NT-proBNP (with modest differences
with respect to the magnitude of elevation of each), it is dangerous
to necessarily ascribe such phenomena entirely to differential depen-
dence on renal clearance. Indeed, early mechanistic studies of renal
function and natriuretic peptides suggest the kidneys clear both
markers equally (and at only 20%) (4).
The interaction between natriuretic peptides and CKD is a
complex one; we concede the potential for difficulties in interpre-
tation of NT-proBNP concentrations in those with impaired
kidney function, but we strenuously emphasize that this is a
circumstance that also hinders use of BNP (5). In summary, the
available data do not support a clinically meaningful difference
between NT-proBNP and BNP in those with CKD, and the data
contradict the tacit suggestion by Lamb and colleagues that BNP
is superior to NT-proBNP in those with impaired renal function.
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